Drug Therapy of BPH: Is Combination Therapy with 5α-Reductase Inhibitors and α-Receptor Blockers Useful?

    September 2002 in “ Der Urologe ”
    Wolfgang Horninger, Georg Bartsch
    TLDR Combination therapy is more effective for prostate volumes over 60 ml.
    The document discussed the use of 5α-reductase inhibitors and α1-receptor blockers as primary drug therapies for symptomatic benign prostatic hyperplasia (BPH). It evaluated the potential benefits of combining these therapies through several placebo-controlled studies, including the VA, ALFIN, PREDICT, and MTOPS studies. Results showed a statistically significant benefit for groups receiving α1-receptor blockers and combination therapy compared to placebo and finasteride monotherapy in terms of symptom scores and peak urine flow rates. However, no significant advantage was found for combination therapy over α1-receptor blockers alone. The studies suggested that for patients with prostate volumes up to 40–45 ml, adding a 5α-reductase inhibitor to α1-receptor blocker therapy was not beneficial. In contrast, for patients with prostate volumes over 60 ml, combination therapy might be more effective.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 162 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community NW5 at 19. How many grafts do I need?

      in Transplants  138 upvotes 2 years ago
      A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.
      Can I still save my hairline at age of 15?

      community Can I still save my hairline at age of 15?

      in General  478 upvotes 3 weeks ago
      A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 2 years ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.

    Related Research

    5 / 5 results